title: MTOR mutations in the crosshairs of targeted therapy.
abstract: The identification of genetic lesions that affect tumor sensitivity to targeted therapies is a major objective of precision medicine. Two reports in this issue combine tumor genome analyses with functional characterization to uncover activating mutations in MTOR that confer sensitivity to a clinically used mTOR inhibitor.
authors.affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Rejto
authors.forename: Robert T
authors.initials: RT
authors.lastname: Abraham
mesh_terms: D019008:Drug Resistance, Neoplasm; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases